Introduction

The field of vision restoration took a major step forward with the PRIMA system, a retinal implant designed to bring back functional sight for people living with advanced age-related macular degeneration. Unlike treatments that focus on drugs or surgery, PRIMA uses a light-sensitive implant paired with smart glasses to bypass damaged photoreceptors and stimulate remaining healthy retinal cells.

What Happened

Science Corporation’s PRIMA system recently received approval in Europe and is awaiting FDA clearance in the United States. The technology combines a tiny implant placed in the eye with camera-equipped eyeglasses that capture real-world scenes and convert them into infrared signals. After a period of training, more than 80% of recipients were able to read, complete crosswords, and use their phones again—a significant outcome for a condition that previously had no approved vision-restoring options.

Why This Matters

Age-related macular degeneration affects more than 5 million people worldwide, causing atrophy in the retina’s light-detecting cells. PRIMA’s approach is significant because it targets only the photoreceptors that have died, leaving the rest of the retinal circuitry intact. By transmitting visual information directly to healthy bipolar and ganglion cells, the system leverages the eye’s natural processing pathways. The implications extend beyond individual patients, offering a template for future neural interface therapies in neurology and beyond.

Key Takeaways

  • The PRIMA implant contains 378 pixels, each with photovoltaic cells that convert light into electrical signals and power the chip wirelessly.
  • Glasses with a front-facing camera capture scenes at roughly 5 megapixels and 30 frames per second, transmitting data via a fiber-optic connection to a handheld processor.
  • Users can adjust contrast, brightness, and zoom using physical buttons on the processor, which can be worn on a table or in a pocket.
  • Near-infrared light at 880 nanometers delivered through the pupil activates the implant without causing discomfort.
  • Over 80% of trial participants regained the ability to perform daily tasks like reading and using mobile devices.

Conclusion

The PRIMA system represents a paradigm shift in how advanced macular degeneration is treated. By replacing the function of damaged photoreceptors with a light-powered implant and smart eyewear, it offers thousands of patients a practical way to regain independence in reading, navigation, and digital device use. As the technology moves toward FDA approval, it could redefine the standard of care for age-related vision loss and accelerate research into similar bioelectronic medicine approaches.